Company: STAA
Filing Date: 2025-10-06
Form Type: DFAN14A
Source: 0001213900-25-096599
Chunk: 1

Company: STAAR SURGICAL CO
Filing Date: 2025-10-06
Form: DFAN14A
Chunk 1
---
, postponements, reschedulings or continuations
thereof, the “Special Meeting”). The Participants have filed a definitive proxy statement on Schedule 14A (the “Definitive
Proxy Statement”) and accompanying GREEN Proxy Card to be used in connection with any such solicitation of proxies
from the Company’s stockholders for the Special Meeting. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS HAVE FILED OR WILL FILE WITH THE U.S. SECURTIES AND EXCHANGE COMMISSION (THE “SEC”) BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE SPECIAL MEETING AND additional information relating to the Participants and their direct or indirect interests, by security holdings or otherwise. The Definitive Proxy Statement and accompanying GREEN Proxy
Card have been furnished to some or all of the Company’s stockholders and will be, along with other relevant documents, available
at no charge on the SEC’s website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on September 26, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood
Partners Issues Letter to STAAR Surgical’s Board
Questioning Its Judgment in Proposed Sale to Alcon

Contends There Is No Business Justification for the Board’s
Decision to Sell the Company for $28 Per Share Now After
Rejecting $58 Per Share from Alcon Last Year

Encourages Shareholders to Vote “ AGAINST” the Proposed Acquisition</div>

NEW YORK--(BUSINESS WIRE)--Broadwood
Partners, L.P. and its affiliates (collectively, “Broadwood”)
today issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or
the “Company”) (NASDAQ: STAA). Broadwood, which owns 27.5% of STAAR’s outstanding common shares, continues to urge its
fellow shareholders to vote on its GREEN Proxy Card “AGAINST” the proposed acquisition of STAAR
by Alcon Inc. (“Alcon”) (NYSE: ALC).

Shareholders can find additional information